23. Pulmonary Hypertensive Crisis in the ICU

Quick Recap

Cardiovascular System, new protocol. Companion to Acute Right Ventricular Failure (Cardiovascular System) and Chronic Thromboembolic Pulmonary Hypertension & Pulmonary Endarterectomy (Cardiac Surgery Critical Care) — addresses acute decompensation in patients with known or new pulmonary hypertension, with two genuinely critical, easily-missed rebound/withdrawal phenomena that can turn a stable patient into a crisis.

1. Definition

Pulmonary hypertensive crisis: acute, severe elevation in pulmonary vascular resistance causing acute RV failure — occurring either as an acute decompensation in a patient with known chronic pulmonary hypertension, or as new/perioperative pulmonary hypertension (e.g., after congenital heart surgery, cardiac surgery generally, or as a complication of ARDS). This population is a particular challenge in critical illness because typical ICU therapies — volume resuscitation and mechanical ventilation — can actively worsen hemodynamics rather than help, a genuine inversion of usual ICU reflexes.

2. Two Critical, Easily-Missed Rebound/Withdrawal Phenomena

Never Abruptly Stop Chronic Oral PAH Therapy

Sudden discontinuation of sildenafil (or other PDE5 inhibitors) is associated with clinical decompensation and RV failure. This protocol recommends continuing PDE5 inhibitor therapy through ICU admission in the hemodynamically stable patient — a genuinely easy-to-overlook detail during a busy ICU admission medication reconciliation, where a chronic oral pulmonary vasodilator can be mistakenly held "until things stabilize" — exactly the wrong instinct for this specific drug class. Sildenafil has a short half-life (4 hours, dosed three times daily); tadalafil's longer half-life (35 hours, once daily) provides somewhat more buffer, but neither should be casually interrupted.

Inhaled Nitric Oxide Rebound on Cessation

Inhaled nitric oxide (iNO) can cause rebound pulmonary hypertension on cessation — alongside its other limitations (cost/availability, risk of methemoglobinemia). This protocol treats iNO discontinuation as requiring a deliberate, gradual wean, not an abrupt stop — the same underlying principle as the oral-agent-withdrawal caution above: this drug class's abrupt removal can precipitate the exact crisis it was being used to prevent.

3. A Critical Drug Interaction

PDE5 inhibitors (sildenafil, tadalafil) and nitrates are absolutely contraindicated together — the combination carries a high risk of significant, potentially catastrophic systemic hypotension. This is a genuinely important medication-reconciliation check, particularly relevant if a patient on chronic PAH therapy develops chest pain or ACS-like symptoms in the ICU and nitroglycerin is reflexively considered.

4. Treatment Approach

Address the Underlying Cause First

Treatment of pulmonary hypertension resulting from critical illness or chronic lung disease should primarily address the underlying cause — pulmonary vasodilators are often NOT necessary if the reversible precipitant (hypoxia, acidosis, hypercapnia, ARDS) is corrected. This protocol treats reflexive pulmonary vasodilator initiation, without first addressing a clearly reversible precipitant, as a genuine management error — consistent with the broader RV failure protocol's emphasis on cause-directed rather than generic management.

Oxygen as a Genuine Pulmonary Vasodilator

Oxygen itself functions as a pulmonary vasodilator in this population and is specifically indicated even for relatively mild desaturation (SaO2 <95%) — in right-to-left shunt physiology/pulmonary hypertensive crisis specifically, oxygen selectively improves pulmonary blood flow and decreases RV afterload, a mechanistic rationale distinct from oxygen's usual role of simply correcting hypoxemia.

Inhaled Therapies for Severe/Refractory Cases

• Inhaled epoprostenol is preferred in most institutions over inhaled nitric oxide, given wider availability and lower cost — a genuinely practical, resource-driven preference rather than a purely efficacy-based one
• Inhaled treprostinil has shown favorable outcomes in some settings, but has not been shown to be reliably delivered in mechanically ventilated or altered-mental-status patients — a real delivery-technology limitation restricting its use in the sicker ICU population that might otherwise benefit most
• Combination inhaled-plus-IV prostacyclin analogue therapy can serve as a temporizing measure while IV therapy is titrated, though most supporting evidence comes from non-Group-1 PH patients requiring escalating therapy for decompensated RV failure or the perioperative setting specifically

Riociguat — An Alternative Oral Pathway

Riociguat (a soluble guanylate cyclase stimulator, distinct mechanism from PDE5 inhibitors) has shown hemodynamic and exercise-capacity improvement in PAH and in residual/inoperable CTEPH (cross-reference Chronic Thromboembolic Pulmonary Hypertension & Pulmonary Endarterectomy, Cardiac Surgery Critical Care, for the RACE trial comparing riociguat against balloon pulmonary angioplasty specifically in that population).

5. A Genuine, Acknowledged Evidence Gap

Very few human studies have directly addressed vasopressor and pulmonary vasodilator selection specifically in critically ill pulmonary hypertension patients — much of the evidence base draws on a combination of limited human data and extrapolation from other populations (including, for iNO specifically, substantial extrapolation from neonatal pulmonary hypertension experience). This protocol treats this as a genuine, honestly-acknowledged evidence gap, consistent with this library's broader practice of not overstating the certainty behind management recommendations in less-studied populations — dobutamine, milrinone, inhaled nitric oxide, and IV prostacyclin have the relatively greatest support in the literature, but this is a comparatively low bar given how sparse the overall evidence base is.

6. Practical Synthesis

1. Continue chronic oral PAH therapy (PDE5 inhibitors) through ICU admission in the hemodynamically stable patient — do not hold it reflexively during medication reconciliation
2. Wean, don't abruptly stop, inhaled nitric oxide once initiated, given the real rebound pulmonary hypertension risk
3. Never combine PDE5 inhibitors with nitrates
4. Address the reversible underlying cause first — don't reflexively add a pulmonary vasodilator before correcting hypoxia, acidosis, or hypercapnia
5. Use supplemental oxygen even for mild desaturation in this population specifically, given its direct pulmonary-vasodilating mechanism
6. Choose inhaled therapy based on institutional availability/cost as much as pure efficacy — epoprostenol is the practical default in most centers
7. Acknowledge the genuine evidence gap in vasopressor/vasodilator selection for this specific population rather than presenting management as more evidence-based than it actually is

7. Consultation Matrix

8. Documentation & Medicolegal Checklist

• Home PAH medications reconciled and continuation/hold decision documented explicitly, with rationale
• iNO wean plan (not abrupt stop) documented
• Explicit medication reconciliation check for nitrate-PDE5-inhibitor interaction documented

9. Key Guidelines

• Management Considerations for Pulmonary Arterial Hypertension Pharmacotherapy in the Intensive Care Unit (2023) provides the most current, ICU-specific synthesis

10. Landmark Evidence

11. Controversies

• The evidence base for vasopressor/pulmonary vasodilator selection in critically ill PH patients remains genuinely sparse — this protocol treats "greatest literature support" (dobutamine, milrinone, iNO, IV prostacyclin) as a relatively low bar given how few dedicated human studies exist, not as strong, high-certainty evidence.
• Inhaled epoprostenol's preference over iNO in most institutions reflects cost/availability as much as demonstrated superior efficacy — a pragmatic, resource-driven pattern rather than a purely evidence-based hierarchy.
• Substantial iNO practice guidance in adults remains extrapolated from neonatal pulmonary hypertension experience — a genuine, acknowledged limitation in the underlying evidence base for this specific therapy.

12. References

1. Management Considerations for Pulmonary Arterial Hypertension Pharmacotherapy in the Intensive Care Unit. Pharmacy (Basel). 2023;11(5):145.
2. Critical care management of pulmonary hypertension. BJA Educ. 2017.
3. Acute and chronic effects of sildenafil and other vasopressors/pulmonary vasodilators in pulmonary hypertension. Semin Cardiothorac Vasc Anesth. 2005.
4. Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery. 2014.
5. Management of pediatric pulmonary hypertension. J Pediatr Crit Care. 2025.
6. Houston BA, Brittain EL, Tedford RJ. Right ventricular failure. N Engl J Med. 2023;388:1111-1125.

See also: Acute Right Ventricular Failure (Cardiovascular System) for the broader RV failure management framework this protocol adds pulmonary-hypertension-specific pharmacology to; Chronic Thromboembolic Pulmonary Hypertension & Pulmonary Endarterectomy (Cardiac Surgery Critical Care) for the surgical/interventional population and riociguat's comparative evidence there; ARDS (Respiratory System) for ARDS-associated pulmonary hypertension as a specific precipitant.